Page 23 of 28 FirstFirst ... 13141516171819202122232425262728 LastLast
Results 221 to 230 of 277

Thread: Doctors in China carry out world first spine surgery

  1. #221
    Senior Member Tim C.'s Avatar
    Join Date
    Oct 2002
    Location
    New Jersey
    Posts
    2,208
    Blog Entries
    1
    Quote Originally Posted by 朽木Greg View Post
    I am definitely interested in the therapy/rehab they have him doing now. I've been living in Chengdu (definitely not as big as Tianjin, but it's the capital of sichuan province) since September, and have been disappointed with the therapy provided here, especially at the best hospital in the area, the specifically treats SCI (not many, if any, others do). I guess I'm comparing it to American therapy, which sets the bar high, but the therapy provided here is not intensive. And there is a huge focus on Traditional Chinese Medicine, which i have yet to see any noticeable effects on my recovery, and i am guessing that this patient ("Liu") is receiving some TCM. Really wondering about his post-surgery treatments.
    Greg, hello, this your first post? So are you there just to receive physical rehab or are you hoping to get into the surgery trials, or have you already, or what?

  2. #222
    well i lived here before my injury, which was in June 2013. I had set it as my goal to return, and i did in September 2014. I have no current plans to join these surgery trials, the functionality I have recovered is great, and don't want to risk losing it for this still experimental surgery. However, 5 years down the line, if this has become a success, I would consider it. I am currently using forearm crutches to get around, but if I had still been in my chair when i returned to china, life would be very difficult. Whatever China's form is of the ADA, does not do a great job of regulating things and making sure accessibility is provided. Also, squat toilets being the prevalent style of toilet does not make it easier.

  3. #223
    Senior Member Tim C.'s Avatar
    Join Date
    Oct 2002
    Location
    New Jersey
    Posts
    2,208
    Blog Entries
    1
    O
    Quote Originally Posted by 朽木Greg View Post
    well i lived here before my injury, which was in June 2013. I had set it as my goal to return, and i did in September 2014. I have no current plans to join these surgery trials, the functionality I have recovered is great, and don't want to risk losing it for this still experimental surgery. However, 5 years down the line, if this has become a success, I would consider it. I am currently using forearm crutches to get around, but if I had still been in my chair when i returned to china, life would be very difficult. Whatever China's form is of the ADA, does not do a great job of regulating things and making sure accessibility is provided. Also, squat toilets being the prevalent style of toilet does not make it easier.
    Sounds like you got enough of a risk just moving back to china post injury, you even have SCI? In any case you suggest you're ambulatory for the most part. Best of luck.

  4. #224
    Quote Originally Posted by Tim C. View Post
    Sounds like you got enough of a risk just moving back to china post injury, you even have SCI? In any case you suggest you're ambulatory for the most part. Best of luck.
    ya, i gave up some quality rehab time in america by pursuing my career here. i am a c4 incomplete. i'll keep everyone updated with anything i hear from inside China.

  5. #225
    Greg,

    A friend of ours has been living in China for several years now- http://sci.rutgers.edu/forum/showthr...t-film-(China)

  6. #226
    Cool! I knew i couldn't have been the only one

  7. #227
    髓损伤临床研究
    脊髓损伤多见于交通事故、砸伤、摔伤、运动性损伤和一些如地震、矿难等自然灾难。在中国,工伤和交通事故造 成脊髓损伤的案例更为常见,我国现有脊髓损伤患者超过两百万人。脊髓损伤患者以青壮年为主,高发年龄段集中 在18-32岁。脊髓损伤后劳动能力几乎完全丧失,加上昂贵的治疗康复费用,给家庭和社会造成巨大负担。
    脊髓损伤修复是世界医学难题。脊髓损伤后,由于损伤及其继发的一系列的病理生理反应,包括缺血缺氧、胶质瘢 痕生成以及机体免疫反应等,导致轴突和髓鞘分解,甚至神经元胞体死亡,致使渐进性的神经组织丢失,在损伤部 位形成空洞或瘢痕。在脊髓损伤患者中,这种空洞或瘢痕经常横跨整个脊髓节段,从而阻断脊髓神经传导通路,导 致感觉运动功能丧失。脊髓损伤患者除了原发性的脊髓损伤外,常伴有并发症的发生,几种常见的并发症有压疮、 泌尿系统并发症、呼吸系统并发症、深静脉血栓及肺栓塞、痉挛、疼痛、植物神经过反射、骨质疏松等,这些并发 症不但影响康复治疗的效果及进程,还严重影响患者的生活质量,甚至威胁到患者的生命。
    再生医学的发展为脊髓损伤治疗提供了希望。胶原蛋白是细胞外基质的主要成分。以胶原蛋白为基质的生物材料产 品已大量用于凝血、烧伤、骨、肌腱、硬脑膜、外周神经等组织损伤修复的临床治疗,被证明有较好的生物相容性 。戴建武团队自2003年起始一直致力于神经再生胶原支架材料的研发,研制了适合脊髓损伤修复的神经再生胶 原支架。建立了大鼠及比格犬长距离脊髓全横断缺损的损伤模型,研究神经再生胶原支架及其功能化形式(如结合 生长因子或者干细胞)引导神经再生以及促进脊髓损伤功能的恢复。在大动物犬的急性和慢性脊髓全横断缺损的损 伤模型中,共进行了5批次共计近170只比格犬的研究,长期观察发现功能生物材料能够有效促进动物运动功能 恢复,包括站立及行走。2014年初与中国食品药品检定研究院医疗器械检定研究所合作制订了神经再生胶原支 架的产品标准并进行型式检测。
    间充质干细胞不仅具有较强的自我更新和多向分化能力,而且还有免疫调节作用。研究表明,一方面间充质干细胞 可分泌大量的神经营养因子包括 BDNF、GDNF、VEGF、FGF-2、NGF、NT-3 等,这些营养因子对于继发性脊髓损伤中神经干细胞的存活、脊髓组织保留以及运动功能恢复具有重要作用。另一 方面间充质干细胞还可通过各种方式,作用于 T 淋巴细胞、B 淋巴细胞和自然杀伤细胞 (NK细胞),抗原递呈细胞等免疫细胞,通过调节其增殖、分化和活化,从而影响机体免疫状态,调节机体免疫 反应,促进脊髓损伤修复。
    在完成一系列动物实验的基础上,我们于2014年下半年组建了以戴建武为负责人的脊髓损伤临床研究团队,除 了核心技术人员外,还包括合作医院的临床专家、康复专家、心理咨询专家及营养专家。于2015年初启动了神 经再生胶原支架结合间充质干细胞治疗脊髓损伤的临床研究。中国科学院“干细胞与再生医学研究”先导专项将支 持临床研究费用,具体包括研究期间的手术费用,康复费用及相关心理咨询费用。脊髓损伤临床研究分为两个阶段 。第一阶段计划进行5-6例手术通过6-8周的研究评估手术的安全性及进一步完善手术方案。截止2015年1月底已完成第一阶段的手术目标及完成了 5例患者的手术。分别是1月16日和1月19日在中国武警脑科医院(天津)进行的第一和第二例,1月21日 在苏州大学附属第一医院(苏州)进行的第三例,1月23日和1月30日在解放军总医院第一附属医院(北京) 进行的第四和第五例。
    四月初完成了5个病例的4周和8周安全评估报告(见附件)。安全评估报告表明通过电生理仪检测清除胶质瘢痕 及植入胶原支架材料是安全的。这是脊髓损伤临床研究的重要进展。在此基础上,我们于2015年4月19日启 动了第二阶段有效性研究,计划入组病例20至25例,并进行系统康复训练,进行为期1年的有效性观察。在5 月31日,第二阶段病例入组顺利完成。完成了21例病例入组。我们将系统总结手术方式和适应症特点,优化康 复程序,于合适时间开展第三阶段临床研究,预计入组病例20例左右。
    参与脊髓损伤临床研究的医院联系方式:
    中国武警脑科医院(天津):
    联系人:韩医生、云医生
    电话:022-60577134
    邮箱:wjnkyyn12@126.com
    苏州大学附属第一医院(苏州):
    联系人:周医生、史医生
    电话:0512-67780101
    邮箱:sdfyyspine@163.com
    解放军总医院第一附属医院(北京):
    联系人:杨医生、梁医生
    电话:010-66848873
    邮箱:spinalcord304tang@163.com
    中南大学湘雅医院(长沙):
    联系人:蒋医生、王医生、刘医生
    电话:0731-89753735
    邮箱:xysjwk@163.com
    同济大学附属同济医院(上海):
    联系人:徐医生,程医生
    电话:021-66111706
    邮箱:lorings@163.com
    附件1:神经再生胶原支架移植治疗脊髓损伤的临床研究4周安全性评估报告(2015年3月18 日) 
    脊髓损伤修复是世界性医学难题。在中国科学院“干细胞与再生医学研究”战略性先导科技专项的支持下,中国科 学院遗传与发育生物学研究所戴建武研究团队在十余年来生物材料研发及动物实验取得良好损伤修复效果的基础上 ,组建了以戴建武为负责人的脊髓损伤临床研究团队并于2015年初开展了神经再生胶原支架结合间充质干细胞 治疗脊髓损伤的临床研究。
    该临床研究计划分为两个阶段:第一阶段评估手术安全性。在手术后4周和8周评估手术后的安全程度,对手术过 程及神经支架材料的移植后的反应进行评估;第二阶段评估临床研究的有效性。在8周安全评估无不良作用的前提 下,将于4月中旬进行20-30例左右的临床手术,并开展康复训练,心理咨询,进行为期一年的 有效性评估。
    第一阶段临床研究2015年1月份开始,在合作的三家临床医院进行了5例脊髓损伤修复手术。手术过程顺利。 通过临床研究第一阶段第1个月的临床观察,5名患者未见与神经再生胶原支架、干细胞移植以及手术清除瘢痕相 关的不良反应,包括感染、急性排斥反应、伤口愈合不良、神经功能明显恶化等不良反应。研究团队认为实验方案 可行,手术安全性良好。脊髓损伤临床研究4周的安全评估结果表明神经再生胶原支架结合间充质干细胞治疗脊髓 损伤的临床研究在以下两个方面取得了重要进展:1)本研究首次探索了采用电生理等手段区分神经组织和瘢痕组 织,并实施了对瘢痕组织的手术清除。该手术的成功意味着脊髓神经再生的物理障碍可以被手术清除。2)首次进 行了神经再生支架的移植并初步证明是安全的。这在脊髓损伤后形成的空洞及瘢痕去除后的缺损处搭起了引导神经 再生的桥梁。
    在8周安全评估无明显副作用前提下,拟在4月初完成安全评估报告后即开展第二阶段的临床研究。第二阶段临床 研究拟增加同济大学附属同济医院(上海)等医院加入临床研究团队(拟新增加的医院最终能否加入将根据对其手 术方案审查,医院的伦理审查以及相关备案等工作的结果来确定)。预计筛选临床研究患者20-30例,术后进行系统康复训练、心理干预和营养调节,通过1年左右的临床观察,对疗效进行初步评估 .
    附件2:神经再生胶原支架移植治疗脊髓损伤的临床研究2个月安全性评估报告(2015年4月7 日)
    中国科学院遗传与发育生物学研究所戴建武研究团队在十多年生物材料研发及动物实验的基础上,开展了以戴建武 为负责人的脊髓损伤临床研究。于2015年初开展了神经再生胶原支架结合细胞治疗脊髓损伤的临床研究的第一 阶段。第一阶段临床研究主要目的是评估手术安全性。共入组5名慢性脊髓全横断患者,最后一名患者于2015 年1月30日完成手术。至3月31日截止,已历时两个月。经过两个月的临床观察,所有患者未见与神经再生胶 原支架、细胞移植以及手术清除瘢痕相关的不良反应,包括感染、急性排斥反应、伤口愈合不良、神经功能明显恶 化等。临床研究团队认为实验方案可行,手术安全性良好。目前5名患者正在积极开展术后的康复训 练。
    神经再生胶原支架移植治疗脊髓损伤的临床研究现开始第二阶段有效性研究。拟增加中南大学湘雅医院、同济大学 附属同济医院(上海)等医院加入临床研究团队(拟新增加的医院最终能否加入将根据对其手术方案审查,医院的 伦理审查以及相关备案等工作的结果来确定),目前各参加医院已开始筛选患者,预计筛选临床研究 患者20-30例。术后将进行系统康复训练、心理干预和营养调节,通过1年左右的临床观察,对疗效进行评估。

  8. #228
    Cord injury clinical researchSpinal cord injury is more common in accidents, injured, falls, sports injuries and some, such as earthquakes, mine and other natural disasters. In China, injuries and traffic accidents are more common cases of spinal cord injury, spinal cord injury patients with existing country more than two million people. Spinal cord injury patients are young, high-fat concentrated in the 18-32 years age group. After spinal cord injury is almost completely lost the ability to work, plus the cost of expensive treatment and rehabilitation, to create a huge burden on families and society.
    Spinal cord injury is a medical problem in the world. After spinal cord injury, due to damage and a series of secondary pathophysiological responses, including ischemia and hypoxia, glial scar generation, and the immune response, leading to axon and myelin decomposition, even the death of neurons, resulting in progressive loss of nerve tissue in the injury site or scar formation of voids. In patients with spinal cord injury, which often voids or scar across the entire spinal segment, thereby blocking the spinal nerve pathways, resulting in loss of sensory and motor function. In addition to the primary spinal cord injury patients with spinal cord injury, often accompanied by complications, several common complications of pressure sores, urinary complications, respiratory complications, deep vein thrombosis and pulmonary embolism, spasm, pain Effects and processes, autonomic over reflection, osteoporosis, etc. These complications not only affect the rehabilitation, but also seriously affect the quality of life of patients, even a threat to the lives of patients.
    Regenerative medicine development offer hope for the treatment of spinal cord injury. Collagen is the major component of the extracellular matrix. With collagen matrix biomaterial products have been widely used blood clotting, burns, bone, tendon, epidural, peripheral nerve clinical tissue repair, been shown to have good biocompatibility. Dai Jianwu team since the start of 2003 has been committed to the development of nerve regeneration collagen scaffolds, developed a collagen scaffold for nerve regeneration in spinal cord injury repair. The establishment of a long-distance Beagles rat spinal cord injury model and defects, neural regeneration collagen scaffold and functional forms (such as binding growth factor or stem cell) guided nerve regeneration and promote recovery of function in spinal cord injury. In large animal injury model in dogs with acute and chronic spinal cord defects in completely transected, were carried out in five batches totaling nearly 170 beagles study, long-term observation discovery of biological material that can effectively promote animal recovery of motor function, including standing and walking. Early 2014 in cooperation with the Chinese Institute of Food verification test Institute for Drugs and Medical Devices has developed nerve regeneration collagen scaffold product standards and type testing.
    Mesenchymal stem cells not only has a strong capability of self-renewal and differentiation, but also immunomodulatory effects. Studies have shown that, on the one hand mesenchymal stem cells can secrete large amounts of neurotrophic factors include BDNF, GDNF, VEGF, FGF-2, NGF, NT-3, etc. These nutritional factors for the survival of secondary spinal cord injury in neural stem cells in the spinal cord tissue retention and recovery of motor function has an important role. On the other hand mesenchymal stem cells can also be a variety of ways, the role of T lymphocytes, B lymphocytes and natural killer cells (NK cells), antigen presenting cells and other immune cells by regulating the proliferation, differentiation and activation, thereby Effect of immune status, regulate the immune response, promote the repair of spinal cord injury.
    We completed a series of animal experiments, based on the second half of 2014 we set up to 戴建武 responsible person with spinal cord injury clinical research team, in addition to core technical staff, including clinical experts to hospitals, rehabilitation specialists, psychological consultants and nutrition experts. In early 2015 launched a clinical study of nerve regeneration collagen scaffold combined with mesenchymal stem cells to treat spinal cord injuries. Chinese Academy of Sciences "stem cells and regenerative medicine" Pilot projects will support clinical research expenses, including the cost of surgery during the study period, rehabilitation costs and related counseling costs. Spinal cord injury clinical study is divided into two stages. The first phase of the program were 5-6 cases of surgical procedure to assess the safety and to further improve the operation scheme by 6-8 weeks of the study. As of the end of January 2015 it has completed the first phase of the operation objectives and the completion of the patient's surgery in 5 cases. Are first and second cases, the third example in the First Affiliated Hospital of Soochow University (Suzhou) conducted January 21 in the Chinese armed Brain Hospital (Tianjin) conducted on January 16 and January 19, 1 The fourth and fifth cases in the First Affiliated Hospital of PLA General Hospital (Beijing) conducted on 23 and 30 January.
    Early April to complete the 5 cases of four weeks and eight weeks safety evaluation report (see Annex). Safety Evaluation Report showed clear glial scar and implant collagen scaffold is secure by electrophysiological detected. This is an important progress in clinical studies of spinal cord injury. On this basis, we are on April 19, 2015 started the second phase of the effectiveness of research, planning the group of patients from 20 to 25 cases, and system rehabilitation, observe the validity period of 1 year. In May 31, the second phase of the cases the group successfully completed. He completed 21 cases into groups. We will summarize surgical system characteristics and indications, optimizing rehabilitation program, the third phase of clinical research carried out at the appropriate time, the group is expected around 20 cases.
    Spinal cord injury clinical research participation Hospital Contact:
    Chinese People's Armed Police Brain Hospital (Tianjin):
    Contact: Dr. Han, cloud doctors
    Tel: 022-60577134
    E-mail: wjnkyyn12@126.com
    First Affiliated Hospital of Soochow University (Suzhou):
    Contact: Dr. Zhou, Dr. Shi
    Tel: 0512-67780101
    E-mail: sdfyyspine@163.com
    First Affiliated Hospital of PLA General Hospital (Beijing):
    Contact: Dr. Yang, Dr. Liang
    Tel: 010-66848873
    E-mail: spinalcord304tang@163.com
    Xiangya Hospital, Central South University (Changsha):
    Contact: Dr. Jiang, Dr. Wang, Dr. Liu
    Tel: 0731-89753735
    E-mail: xysjwk@163.com
    Tongji Hospital, Tongji University (Shanghai):
    Contact: Dr. Xu, Dr. Cheng
    Tel: 021-66111706
    E-mail: lorings@163.com
    Annex 1: nerve regeneration collagen stent-graft treatment of spinal cord injury clinical study four weeks Safety Assessment Report (March 18, 2015)
    Spinal cord injury is a worldwide medical problem. In support of Chinese Academy of Sciences "stem cells and regenerative medicine" strategic leading science and technology projects, the Institute of Genetics and Developmental Biology Research Team Dai Jianwu in ten years biomaterials research and animal experiments achieved good effect on the basis of repair , set up to 戴建武 responsible person with spinal cord injury clinical research team and in early 2015 launched a clinical study of nerve regeneration collagen scaffold combined with mesenchymal stem cells to treat spinal cord injuries.
    The clinical research program is divided into two stages: the first stage of the evaluation procedure safety. In 4 weeks and 8 weeks after surgery to assess the safety of surgery, surgical procedures and neurological reaction scaffold after transplantation for evaluation; assess the effectiveness of the second stage of clinical research. In eight weeks the safety assessment under the premise of no adverse effects, will be held in mid-April 20-30 cases of clinical surgery around and carry out rehabilitation training, psychological counseling, conduct a one-year assessment of the effectiveness.
    The first phase of clinical study began in January 2015, in three clinical hospital cooperation were five cases of spinal cord injury repair surgery. Surgery went smoothly. The first phase of clinical research through clinical observation a month, five patients with nerve regeneration in no collagen scaffold, stem cell transplant, and surgical removal of scar-related adverse events, including infections, acute rejection, wound healing, nerve function significantly degradation and other adverse reactions. The research team believes the experiment is feasible, surgical safety is good. Security assessment results of clinical studies indicate that spinal cord injury four weeks between nerve regenerated collagen scaffold binding mesenchymal stem cells to treat spinal cord injury clinical research has made significant progress in the following two aspects: 1) The study is the first to explore other means to distinguish between the use of electrophysiological nerve tissue and scar tissue, and implemented a surgical removal of scar tissue. The success of the operation means that the spinal nerve regeneration physical barriers can be surgical removal. 2) performed the first nerve regeneration stent graft and initially proved to be safe. Voids and defects after removal of scar that formed after spinal cord injury bridges the guided nerve regeneration.
    Safety Assessment no significant side effects in eight weeks under the premise, the second phase of clinical studies to be undertaken in early April after the completion of the safety assessment report. Phase II clinical studies proposed increase in Tongji Hospital (Shanghai) and other hospitals to join the clinical research team (to be newly added hospital can eventually join the program will be based on review of their surgery, the hospital's ethics review and filing and other work-related results determined). Screening of patients with clinical study is expected to 20-30 cases of postoperative rehabilitation system, psychological interventions and nutrition regulation, through clinical observation for about a year, a preliminary assessment of efficacy.
    Appendix 2: Clinical study nerve regeneration collagen scaffold transplantation in spinal cord injury two months safety evaluation report (April 7, 2015)
    Institute of Genetics and Developmental Biology research team in more than a decade Dai Jianwu basic biological materials research and animal experiments and clinical studies in spinal cord injury 戴建武 responsible person carried out. In early 2015 to carry out the first phase of nerve regeneration collagen scaffold binding cells to treat spinal cord injury clinical research. The main purpose of the first phase of clinical study is to evaluate the safety of the operation. Enrolled a total of five patients with chronic spinal cord completely transected, and finally a patient on January 30, 2015 to complete the surgery. Until March 31 deadline, it has lasted for two months. After two months of clinical observation, all patients seen with nerve regeneration in collagen scaffolds, cell transplantation and surgical removal of scar-related adverse events, including infections, acute rejection, wound healing, nerve function was worsening. Clinical research team believes the experiment is feasible, surgical safety is good. Currently five patients are actively engaged in rehabilitation after surgery.
    Clinical study nerve regeneration collagen scaffold transplantation in spinal cord injury, is beginning the second phase of Effectiveness. The proposed increase in Xiangya Hospital, Tongji Hospital, Tongji University (Shanghai) and other hospitals to join the clinical research team (to be newly added hospital can eventually join the program will be reviewed in the light of their surgery, the hospital's ethical review and filing and other related work results to determine), currently participating hospitals have begun screening patients, clinical study is expected to screen patients 20-30 cases. The system rehabilitation after training, psychological interventions and nutrition regulation, through clinical observation for about a year, to assess the efficacy.
    Last edited by Silvio GS; 06-12-2015 at 11:50 AM.

  9. #229
    Senior Member Imight's Avatar
    Join Date
    Nov 2007
    Location
    Philippines
    Posts
    6,535
    Quote Originally Posted by 朽木Greg View Post
    Cool! I knew i couldn't have been the only one
    HA. hows it going. I've been to chengdu, beautiful city, it was the first city I'd ever been too in china. Im currently in qingdao. do you have wechat?

    we have another poster closer to you over in kunming, I texted them but no answer so Im not sure if they moved back to HK or France but her son was getting therapy at Kunming Hospital the one doing the rehabilitation for chinascinet

    as for this study. lookin good, seems the procedure is safe, some patients are starting to feel and even move a bit, means the regeneration is happening. I have a bit more confidence in this study and am following it closely because the chinese govt is involved. the fact that they came public with it is big, because if they didn't have confidence they would have kept this hush hush. they are very PR conscious.

  10. #230
    Yes I believe this trial and the trial in Russia to be the best work in human spinal cord injury currently. It's not just a matter of stem cells it's a matter of the cells with scaffolding or biomaterial, and nwls regeneration matrix is the best biomaterial to date in my opinion.

Similar Threads

  1. Replies: 10
    Last Post: 09-13-2015, 11:15 AM
  2. Replies: 3
    Last Post: 11-14-2011, 09:17 AM
  3. Replies: 1
    Last Post: 12-21-2005, 11:10 AM
  4. Spine doctors raise hope of electric cure
    By CarThief in forum Cure
    Replies: 1
    Last Post: 05-29-2005, 03:42 PM
  5. First Transatlantic Spine Surgeries Bring Doctors Together
    By Leo in forum Health & Science News
    Replies: 0
    Last Post: 12-03-2003, 05:26 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •